CN104256583A - 一种以纳豆冻干粉及银杏叶提取物为主的保健品的配方 - Google Patents
一种以纳豆冻干粉及银杏叶提取物为主的保健品的配方 Download PDFInfo
- Publication number
- CN104256583A CN104256583A CN201410450798.XA CN201410450798A CN104256583A CN 104256583 A CN104256583 A CN 104256583A CN 201410450798 A CN201410450798 A CN 201410450798A CN 104256583 A CN104256583 A CN 104256583A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- formula
- extract
- ginkgo biloba
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 title claims abstract description 27
- 235000013557 nattō Nutrition 0.000 title abstract description 5
- 239000009429 Ginkgo biloba extract Substances 0.000 title abstract description 4
- 229940068052 ginkgo biloba extract Drugs 0.000 title abstract description 4
- 235000020686 ginkgo biloba extract Nutrition 0.000 title abstract description 4
- 239000000463 material Substances 0.000 title abstract 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 22
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 22
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 18
- 239000000284 extract Substances 0.000 claims abstract description 18
- 230000036541 health Effects 0.000 claims abstract description 13
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000019152 folic acid Nutrition 0.000 claims abstract description 11
- 239000011724 folic acid Substances 0.000 claims abstract description 11
- 229960000304 folic acid Drugs 0.000 claims abstract description 11
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 11
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 11
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 11
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 10
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 10
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 10
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229920002472 Starch Polymers 0.000 claims abstract description 9
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 9
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 9
- 235000020717 hawthorn extract Nutrition 0.000 claims abstract description 9
- 239000002002 slurry Substances 0.000 claims abstract description 9
- 235000019698 starch Nutrition 0.000 claims abstract description 9
- 239000008107 starch Substances 0.000 claims abstract description 9
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 9
- 239000011718 vitamin C Substances 0.000 claims abstract description 9
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 9
- 239000011709 vitamin E Substances 0.000 claims abstract description 9
- 229940046009 vitamin E Drugs 0.000 claims abstract description 9
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 7
- 229960003495 thiamine Drugs 0.000 claims abstract description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 7
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 7
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 7
- 244000194101 Ginkgo biloba Species 0.000 claims description 18
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 18
- 244000068988 Glycine max Species 0.000 claims description 15
- 235000010469 Glycine max Nutrition 0.000 claims description 15
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 11
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 11
- 244000046146 Pueraria lobata Species 0.000 claims description 9
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 9
- 239000000470 constituent Substances 0.000 claims description 8
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 7
- 244000182216 Mimusops elengi Species 0.000 claims description 7
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 7
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000000465 moulding Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 235000011201 Ginkgo Nutrition 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 19
- 239000008280 blood Substances 0.000 abstract description 19
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 16
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 13
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 10
- 208000007536 Thrombosis Diseases 0.000 abstract description 7
- 210000004204 blood vessel Anatomy 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 230000002792 vascular Effects 0.000 abstract description 2
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 230000000916 dilatatory effect Effects 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 210000000582 semen Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229940086319 nattokinase Drugs 0.000 description 3
- 108010073682 nattokinase Proteins 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000001662 opsonic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241001092040 Crataegus Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 206010056610 Pseudoangina Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000001471 fibrinogenolytic effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及保健品领域,尤其是一种以纳豆冻干粉及银杏叶提取物为主的保健品的配方,其特征是:本配方按质量配比是:纳豆冻干粉18~22%、银杏叶提取物12~16%、决明子提取物18~22%、葛根提取物18~22%、山楂提取物8~12%、枸杞子粉8~12%、人参提取物3~7%、维生素C0.18~0.22%、维生素E0.013~0.017%、维生素B10.001~0.003%、维生素B60.001~0.003%、维生素B120.000004~0.000007%、叶酸0.0003~0.0006%,其余为淀粉浆,以上各组成成分之和为100%,本发明配方,能有效调节血液粘度、降血脂、溶血栓、扩血管、清除自由基、抗氧化、增强人体免疫力、降低中老年心脑血管疾病发病率,保护中老年人心脑血管系统,促进中老年人群的体质健康发展具有重要积极的意义。
Description
技术领域
本发明涉及保健品领域,尤其是一种以纳豆冻干粉及银杏叶提取物为主的保健品的配方。
背景技术
心脑血管疾病是一种严重威胁人类健康,尤其是在50岁以上中老年人中发病率极高的常见病。全世界每年死于心脑血管疾病的人数高达1500万,居各种死因之首,它已成为导致人类死亡的头号杀手。心脑血管疾病是心血管疾病和脑血管疾病的总称。心血管疾病以冠心病为主,是由于供应心肌血液的冠状动脉发生粥样硬化,使动脉血管变窄,心肌供血不足造成的。由于官腔狭窄或闭塞程度不同,因此可表现为隐性心脏病、心绞痛、心肌梗塞、心肌硬化和心源性猝死等多种形式。脑血管病则是指脑血管破裂出血或血栓形成,引起的以脑部出血性或缺血性损伤症状为主要临床表现的一组疾病,俗称脑中风。西医学认为,心脑血管疾病发病的最主要原因即为动脉粥样硬化,高血脂症是动脉粥样硬化的病理基础,降血脂,预防动脉粥样硬化,是防治心脑血管疾病的核心方法。中医学认为,心脑血管疾病的发生发展,源于本虚导致的脏腑功能失常,痰浊瘀血内生,发展形成为脉络痹阻,最终使心脑器官产生器质性损害,导致功能障碍,引发疾病。治疗预防应针对疾病发展不同阶段的主要病因病机,辩证施治,针对心脑血管疾病,医院里对降血脂的治疗仍以药物干预为主,但由于西药不可避免的副作用,以及药物耐受性等弊端较多,治疗效果远达不到预期。
发明内容
为了解决上述问题,本发明所提供一种以纳豆冻干粉及银杏叶提取物为主的保健品的配方,其技术方案如下:
所述的一种以纳豆冻干粉及银杏叶提取物为主的保健品的配方,其特征是:本配方按质量配比是:纳豆冻干粉18~22%、银杏叶提取物12~16%、决明子提取物18~22%、葛根提取物18~22%、山楂提取物8~12%、枸杞子粉8~12%、人参提取物3~7%、维生素C 0.18~0.22%、维生素E 0.013~0.017%、维生素B1 0.001~0.003%、维生素B6 0.001~0.003%、维生素B12 0.000004~0.000007%、叶酸0.0003~0.0006%,其余为淀粉浆,以上各组成成分之和为100%。
本发明的最佳组合配方按照质量配比是:纳豆冻干粉20%、银杏叶提取物14%、决明子提取物20%、葛根提取物20%、山楂提取物10%、枸杞子粉10%、人参提取物5%、维生素C 0.2%、维生素E 0.015%、维生素B1 0.002%、维生素B6 0.002%、维生素B12 0.000006%、叶酸0.0005%,其余为淀粉浆,以上各组成成分之和为100%。
所述的一种以纳豆冻干粉及银杏叶提取物为主的保健品的配方最终成型剂为颗粒剂剂、胶囊或片剂。
本发明配方的药理及功效总结如下:
1、溶解血栓、降血脂:纳豆中含有的纳豆激酶,是一种有纤溶活性的丝氨酸蛋白酶,它能够直接作用于交联纤维蛋白,活性强,作用迅速,且对纤维蛋白原不敏感,纤溶同时不水解血浆纤维蛋白原,不会引起出血,安全、高效。纳豆激酶可由消化道吸收,是第一个可口服性溶栓成分,它能显著溶解体内外血栓,明显缩短优球蛋白的溶解时间,同时它还能刺激静脉内皮细胞产生纤溶酶原激活剂,从而高效溶血栓,降血脂,对各类心脑血管疾病以及并发症有显著调理作用。除此之外,纳豆还具有抗肿瘤、抗氧化、降血压、抗菌、防止骨质疏松、调整胃肠等多方面的调理保健功能;
2、扩张血管、改善血液循环:银杏叶具有很高的药用价值,是我国传统中药,且被现代药典收录。银杏叶提取物中的银杏黄酮具有扩张冠状血管及其它血管的作用,临床研究表明,银杏叶提取物是三种血管(动脉、静脉和毛细血管)的有效调节剂,能够显著改善微循环,对心脑血管系统疾病、中风以及轻中度老年痴呆均有良效,并且对头晕目眩、耳鸣、失聪、视网膜病变以及癌症也有很好的调理作用。葛根素有扩张脑血管,解除脑血管痉挛,改善微循环,增加脑血流量的作用,对脑缺血产生保护作用;
3、降胆固醇、降脂降压:配方中所含的纳豆激酶及多种黄酮类物质,都有溶解血栓、降低甘油三酯、降低血清胆固醇含量、防治动脉硬化、预防血栓形成的作用。决明子药性寒凉,具有清热明目、润肠通便的功能,对肝风内动,肝阳上亢,肝肾阴虚引起的心血管症状,效果特别明显,而且决明子中的决明子蒽醌具有降血脂、降血压作用。 山楂是健脾开胃、消食化滞、活血化瘀的良药,也是餐桌上的常见水果,同时还具有抗氧化、降血脂、降血压、强心、抗心律不齐、增强免疫力、清除胃肠道有害细菌等作用,经常食用山楂,能显著降低血清胆固醇及甘油三酯,有效防治动脉粥样硬化。
4、清除自由基,抗氧化,保护血管:VC、VE是高效抗氧化剂,能够保护血管内皮细胞,延缓细胞老化, VE能软化血管,具有扩张血管功能;
5、提高免疫力、抗肿瘤:根据药食同源理论,中药成分精确提取,增加脏腑功能代谢,改善内环境,调节人体细胞组织结构,减少疾病的发病率;
6、降低心脑血管危险因子-同型半胱氨酸含量:同型半胱氨酸是继高血脂后心脑血管疾病又一新的独立致病危险因子,它是体内代谢分解蛋氨酸时的副产物,是一种强氧化剂,被认为是启动动脉血管内壁损伤,形成栓块的罪魁祸首。10%的冠心病与同型半胱氨酸水平偏高有关,轻~中度的高同型半胱氨酸血症可使心血管疾病死亡率升高4~6倍,它已成为冠心病等心脑血管疾病又一新致命因素,威胁着人们的健康;
维生素B6在氨基酸代谢过程中发挥着重要作用,它是控制血液中同型半胱氨酸水平的重要因素。维生素B12是活化叶酸代谢过程中的一种重要辅酶。同时科学的补充叶酸、维生素B6、维生素B12,可以使分解同型半胱氨酸的辅酶系统高效工作,能够有效中老年产生的头痛、心悸、胸闷、心慌、假性心绞痛、轻度高血压、高血脂、高血糖等心脑血管症状。
本发明的有益效果是:本发明配方,能有效调节血液粘度、降血脂、溶血栓、扩血管、清除自由基、抗氧化、增强人体免疫力、降低中老年心脑血管疾病发病率,保护中老年人心脑血管系统,促进中老年人群的体质健康发展具有重要积极的意义。
具体实施方式
实施例1:本发明配方的使用规格为1g/袋,每日服用2次,每次服用1-2袋,按上述使用规格取纳豆冻干粉18%、银杏叶提取物12%、决明子提取物18%、葛根提取物18%、山楂提取物8%、枸杞子粉8%、人参提取物3%、维生素C 0.18%、维生素E0.013%、维生素B1 0.001%、维生素B6 0.001%、维生素B12 0.000004%、叶酸0.0003%,其余为淀粉浆,以上各组成成分之和为100%,充分搅匀后加水冲服即可。
实施例2:本发明配方的使用规格为1g/袋,每日服用2次,每次服用1-2袋,按上述使用规格取纳豆冻干粉18%、银杏叶提取物15%、决明子提取物18%、葛根提取物18%、山楂提取物11%、枸杞子粉8%、人参提取物6%、维生素C0.21%、维生素E0.016%、维生素B10.002%、维生素B60.002%、维生素B120.000006%、叶酸0.0004%,其余为淀粉浆,以上各组成成分之和为100%,充分搅匀后加水冲服即可。
实施例3:本发明配方的使用规格为1g/袋,每日服用2次,每次服用1-2袋,按上述使用规格取纳豆冻干粉18%、银杏叶提取物14%、决明子提取物18%、葛根提取物19%、山楂提取物10%、枸杞子提取物9%、人参提取物5%、维生素C0.20%、维生素E0.015%、维生素B10.002%、维生素B6 0.002%、维生素B12 0.000005%、叶酸0.0004%,其余为淀粉浆,以上各组成成分之和为100%,充分搅匀后加水冲服即可。
实施例4:本发明配方的使用规格为1g/袋,每日服用2次,每次服用1-2袋,按上述使用规格取纳豆冻干粉19%、银杏叶提取物13%、决明子提取物19%、葛根提取物19%、山楂提取物8%、枸杞子粉8%、人参提取物3%、维生素C 0.18%、维生素E 0.013~%、维生素B1 0.001%、维生素B6 0.001%、维生素B 12 0.000004%、叶酸0.0003%,其余为淀粉浆,以上各组成成分之和为100%,充分搅匀后加水冲服即可。
Claims (2)
1.一种以纳豆冻干粉及银杏叶提取物为主的保健品的配方,其特征是:本配方按质量配比是:纳豆冻干粉18~22%、银杏叶提取物12~16%、决明子提取物18~22%、葛根提取物18~22%、山楂提取物8~12%、枸杞子粉8~12%、人参提取物3~7%、维生素C 0.18~0.22%、维生素E 0.013~0.017%、维生素B1 0.001~0.003%、维生素B6 0.001~0.003%、维生素B12 0.000004~0.000007%、叶酸0.0003~0.0006%,其余为淀粉浆,以上各组成成分之和为100%,该配方最终成型剂为颗粒剂、胶囊或片剂。
2.根据权利要求1所述的一种以纳豆冻干粉及银杏粉为主的保健品的配方,其特征是:该配方最佳组合配方按照质量配比是:纳豆冻干粉20%、银杏叶提取物14%、决明子提取物20%、葛根提取物20%、山楂提取物10%、枸杞子粉10%、人参提取物5%、维生素C 0.2%、维生素E 0.015%、维生素B1 0.002%、维生素B6 0.002%、维生素B12 0.000006%、叶酸0.0005%,其余为淀粉浆,以上各组成成分之和为100%,该配方最终成型剂为颗粒剂、胶囊或片剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410450798.XA CN104256583B (zh) | 2014-09-05 | 2014-09-05 | 一种以纳豆冻干粉及银杏叶提取物为主的保健品的配方 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410450798.XA CN104256583B (zh) | 2014-09-05 | 2014-09-05 | 一种以纳豆冻干粉及银杏叶提取物为主的保健品的配方 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104256583A true CN104256583A (zh) | 2015-01-07 |
CN104256583B CN104256583B (zh) | 2016-05-11 |
Family
ID=52148268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410450798.XA Active CN104256583B (zh) | 2014-09-05 | 2014-09-05 | 一种以纳豆冻干粉及银杏叶提取物为主的保健品的配方 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104256583B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104799286A (zh) * | 2015-04-30 | 2015-07-29 | 南京中生生物科技有限公司 | 一种用于提高免疫力的组合物及其制备方法 |
CN107125531A (zh) * | 2017-05-04 | 2017-09-05 | 王春志 | 一种参葛枸杞营养素强化固体饮料及其制备工艺 |
CN107184966A (zh) * | 2017-06-19 | 2017-09-22 | 青岛金海宝生物科技发展有限公司 | 一种防治糖尿病及其并发症的药物组合物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102138968A (zh) * | 2010-02-03 | 2011-08-03 | 博辉生物药业(深圳)有限公司 | 纳豆银杏软胶囊 |
CN102872306A (zh) * | 2012-09-25 | 2013-01-16 | 深圳市安美信生物医药科技有限公司 | 治疗心脑血管疾病的复方富硒中药组合物及其制备方法 |
CN103704691A (zh) * | 2013-12-20 | 2014-04-09 | 哈药集团黑龙江同泰药业有限公司 | 一种纳豆蜂胶银杏叶保健食品及其制备方法 |
CN103766904A (zh) * | 2014-01-22 | 2014-05-07 | 重庆师范大学 | 一种具有降脂、通便功能胶囊的制备及其应用 |
CN103908533A (zh) * | 2013-01-08 | 2014-07-09 | 天津天狮生物发展有限公司 | 一种抗氧化的中药组合物、制备方法及用途 |
-
2014
- 2014-09-05 CN CN201410450798.XA patent/CN104256583B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102138968A (zh) * | 2010-02-03 | 2011-08-03 | 博辉生物药业(深圳)有限公司 | 纳豆银杏软胶囊 |
CN102872306A (zh) * | 2012-09-25 | 2013-01-16 | 深圳市安美信生物医药科技有限公司 | 治疗心脑血管疾病的复方富硒中药组合物及其制备方法 |
CN103908533A (zh) * | 2013-01-08 | 2014-07-09 | 天津天狮生物发展有限公司 | 一种抗氧化的中药组合物、制备方法及用途 |
CN103704691A (zh) * | 2013-12-20 | 2014-04-09 | 哈药集团黑龙江同泰药业有限公司 | 一种纳豆蜂胶银杏叶保健食品及其制备方法 |
CN103766904A (zh) * | 2014-01-22 | 2014-05-07 | 重庆师范大学 | 一种具有降脂、通便功能胶囊的制备及其应用 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104799286A (zh) * | 2015-04-30 | 2015-07-29 | 南京中生生物科技有限公司 | 一种用于提高免疫力的组合物及其制备方法 |
CN107125531A (zh) * | 2017-05-04 | 2017-09-05 | 王春志 | 一种参葛枸杞营养素强化固体饮料及其制备工艺 |
CN107184966A (zh) * | 2017-06-19 | 2017-09-22 | 青岛金海宝生物科技发展有限公司 | 一种防治糖尿病及其并发症的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN104256583B (zh) | 2016-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104473249B (zh) | 一种松花粉的液体制剂及其制备方法 | |
CN103263608B (zh) | 一种排毒养颜的中药原粉 | |
CN105213284A (zh) | 一种祛痘保湿霜及其制备方法 | |
CN104208654A (zh) | 一种以地龙蛋白提取物为主的保健配方 | |
CN103230478A (zh) | 一种富硒纳豆制品 | |
WO2016015391A1 (zh) | 治疗心脑血管疾病的药物组合物及其制备方法 | |
CN104256583B (zh) | 一种以纳豆冻干粉及银杏叶提取物为主的保健品的配方 | |
CN101658618B (zh) | 一种解酒护肝复方制剂及应用 | |
CN104644901A (zh) | 心脑血管疾病缓解期长期防治的中药制剂及其制备方法 | |
CN101829189B (zh) | 一种用于治疗复发性过敏性皮炎的中药组合物 | |
KR100679853B1 (ko) | 가죽나무 추출물을 포함하는 천식 및 알러지 질환의 예방또는 치료용 조성물 | |
CN104274808A (zh) | 抗高原反应的中药组合物 | |
KR101622104B1 (ko) | 결명자 추출물 및 지구병 추출물을 포함하는 피부 질환의 예방, 치료 또는 개선용 조성물 | |
KR101157535B1 (ko) | 아토피성 피부염 개선제 조성물 | |
CN105412279A (zh) | 一种降血脂中药保健品 | |
CN1060028C (zh) | 一种主要由谷物瓜菜果组成的健康食品 | |
CN101331948A (zh) | 一种含辅酶q10和螺旋藻的复合保健品 | |
CN111437301A (zh) | 槐花蛹虫草制剂 | |
CN103815507A (zh) | 一种艾叶饮料及其生产工艺 | |
CN105770843A (zh) | 一种心脑血管保健药物组合物 | |
CN118453742A (zh) | 一种治疗缺血性脑卒中的中药组合物及其制备方法 | |
KR20100129040A (ko) | 미생물을 이용한 우황 청심원 원료 함유 건강식품의 제조방법 및 그 제조방법에 의해 제조된 건강식품 | |
CN115487262A (zh) | 一种改善心脑血管、高血压的组合物及其制备方法 | |
US20220313675A1 (en) | Anti-Aging Telomere-Strengthening NAD+ Sirtuin Dietary Supplement Composition | |
CN105944071A (zh) | 一种腹胀、腹痛肚脐贴 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170329 Address after: 471000 Luoyang province high tech Zone Binhe Road, No. 3, building 22, Henan Patentee after: Henan Jiahe Kang biological food technology Co. Ltd. Address before: 471000 Henan city of Luoyang province high tech Development Zone Binhe Road No. 22 building 3 Patentee before: LUOYANG HUAYI BIOTECHNOLOGY CO., LTD. |